Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers: What can we learn from clinical research?

Author： Eichler Hans-Georg Kong Sheldon Grégoire Jean-Pierre

Publisher： Springer Publishing Company

ISSN： 1618-7598

Source： The European Journal of Health Economics, Vol.7, Iss.2, 2006-06, pp. : 129-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The state of medical education research: what can we learn from the outcomes of the UK Research Excellence Framework?

MEDICAL EDUCATION, Vol. 49, Iss. 5, 2015-05 ,pp. : 446-448

John Wiley & Sons Inc

Access to resources Recommend Favorite

What can we learn from psoriasis pharmacogenomics research?

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 1, 2018-01 ,pp. : 17-17

John Wiley & Sons Inc

Access to resources Recommend Favorite

What can the NHS and pharmaceutical research colleagues learn from each other? Transferability of best practice in the pursuit of research excellence

By Nelson Catherine

Quality in Primary Care, Vol. 15, Iss. 2, 2007-04 ,pp. : 113-118

Radcliffe Press

Access to resources Recommend Favorite

What can we learn from ‘dropouts’ in clinical trials?

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : 318-319

John Wiley & Sons Inc

Access to resources Recommend Favorite

B‐type natriuretic peptide and heart failure: what can we learn from clinical trials?

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol. 42, Iss. 9, 2015-09 ,pp. : 881-887

John Wiley & Sons Inc

Access to resources Recommend Favorite